You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The trials are part of the second phase of the Implementing Genomics in Practice program, which is slated to receive $42 million in funding over 5 years.
This new VC round brings the cancer informatics and precision medicine company's total fundraising to $520 million and its valuation to $3.1 billion.
The Atlantic looks into time spent pursuing gene leads generated through candidate gene studies.
To understand the evolution of brain conditions and other traits, investigators plan to sequence human and pathogen DNA in thousands of samples from Europe.
The Washington Post reports on the use of genetic tests to guide antidepressant treatment.
Researchers used a genome-wide association study to identify seven loci associated with ASD and other conditions, along with five loci linked to ASD alone.
Two independent teams described potential roles for gut microbes, and the compounds they produce, in schizophrenia, depression, and mental quality of life.
The findings underscored links between depression and other conditions and suggested a number of potential new targets for treatment with existing drugs.
Polygenic risk scores for depression, bipolar disorder, and schizophrenia are associated with depression in a general population cohort.
Using UK Biobank and 23andMe data, researchers found 352 loci influencing sleep time preferences, including sites near brain- and retina-expressed genes.
Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.
23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.
The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.
In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.